Palvella Therapeutics (PVLA) Cash from Operations Growth (3y) (2016 - 2026)
Palvella Therapeutics (PVLA) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 34.32% |
| 10 | Palvella Therapeutics | 1.83 Bn | 1.57 Bn | - | 0.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.29% |
| Dec 31, 2025 | 27.61% |
| Sep 30, 2025 | 3.45% |
| Jun 30, 2025 | 29.61% |
| Mar 31, 2025 | 33.14% |
| Dec 31, 2024 | 21.01% |
| Sep 30, 2024 | 42.58% |
| Jun 30, 2024 | -27.11% |
| Mar 31, 2024 | 55.06% |
| Dec 31, 2023 | 52.18% |
| Sep 30, 2023 | -8.70% |
| Jun 30, 2023 | -11.16% |
| Mar 31, 2023 | 10.09% |
| Dec 31, 2022 | 2.55% |
| Sep 30, 2022 | 11.47% |
| Jun 30, 2022 | -13.22% |
| Mar 31, 2022 | -14.44% |
| Dec 31, 2021 | -6.51% |
| Sep 30, 2021 | -0.29% |
| Jun 30, 2021 | 74.65% |